The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Only matter of time before the LFT debacle blows up. A Secondary school of a 1000 pupils in Liverpool was tested twice a few weeks apart, with zero positive results. Probably a reason they're not releasing the Liverpool stats
My daughter's whole secondary school had mass testing in Liverpool today. They used the LFD. Most surprising thing was the pupils carry out the swabbing themselves and pass the swab to an army officer. Asking 11 year olds to swab themselves will invariably lead to more false negatives. I'm afraid the government seem happy to have false negatives (until it's reflected in the death toll. )
Stockopedia have a 'guru' section where they apply the trading 'rules' of 7 different traders.
Stockopedia is receommended by the Naked Trader in his books.
Ironic that Naked trader is the only guru on Stockopedia to lose money over 5 years, 12% loss in fact.
The other strategies all profit over 5 years with the best being Piotroski's trading rules at 202%.
I like the book ' The Naked Trader', seems a decent guy, but he himself admits he's not always right, here's hoping!
Price stalled as hard for new investors to gauge at the moment. Would like an RNS with updated sales. Fundamentally to date we have a market cap of 168 million and sales of 120million, sales of £30million/month. Astounded the sp is at this level.
What a spot! Great to see primerdesign kits used in Pakistan.
Pakistan had record infections over the weekend and have just eased lockdown. Their government is aiming for 30,000 tests a day in June. Global market for the product is on the up. Reassuring we supply 130 countries.
One of the companies on the list is Seegene, a S Korean testing company. They're a S Korean version of NCYT but slightly ahead of the curve. Gives us a real world indication of our possibilities.
In the whole of 2019 Seegene made £80million
In April 2020 Seegene produced 1 million Covid 19 tests
Seegene's market cap is currently £1.84 billion, ours is £162million...! NCYT is so undervalued IMO.
Paul
China and S Korea have nailed the virus and they use they use PCR tests like NCYT.
You need to let them know they're doing it all wrong.
Again, I ask what amazing tests do you recommend China and S Korea change to?
Any? None?
Check out a great S Korean Covid testing company Seegene:105 million USD revenue, producing 1million tests/month and market value of 2 Billion. Sound familiar?
From Forbes April issue
Paul, to quote you 'my opinion is that they are burning thru the nova tests and getting ready for the new faster tests from different companies.'
Name me a covid company making £1million/day?
Name me these amazing new tests you talk of?
Any? None?
The respiratory diagnosis market was worth 5 billion in 2016 and the largest market share was the US. As you know we're awaiting US figures. There's a lot of money to be made and we're at the forefront.
Paul, its not as bad as you paint.
Yes, Zimbabwe placed an order of 1.5million.
Say £7.50/test x 1.5million=£11,250,000 from Zimbabwe.
That leaves £18,750,000 profit from the rest of the orders.
I don't see what's bad about that. The global reach of NCYT is a huge advantage. We can tap into any location the virus rears it's head. Small, light and nimble.
(the example above is the worst case, we don't even know of the 30 million profit included 500k initial or 1.5million total test order)
Paul
When you say NCYT have no substantial orders, they made £30 million in May since the last update, that's £1million per day. They're selling now and have new faster tests to come next month.
NCYT are the gold standard. What are these other new faster better tests you mention, the ones that'll finish Ncyt, care to name them?
Respiratory Disease Testing Market Size, Share & Trends Analysis Report Apr 2017 confirmed: ‘The global respiratory disease testing/diagnostics market size was valued at USD 5.0 billion in 2016 and is expected to grow at a CAGR of 3.3% over the forecast period.' and 'North America the largest market share in 2016. ‘
Bear in mind this report was produced before Covid 19.
More recent May 2020 research from Meticulous Research®,estimates the infectious disease diagnostics market is expected to grow at a CAGR of 7.4% from 2020 to reach $23.17 billion by 2027.
‘North America the largest market share in 2016’: We haven’t even released figures from the US. Newly appointed US sales manager will see we gain market share of the $5 BILLION.
A solid growing war chest will see we expand to gain a decent market share of the future $27BILLION (27,000,000,000!)
NCYT have gone from 12Million revenue in 12 months to 120Million revenue in 3 months and still growing. From minnow to 'gold standard' , get in at the start of this journey.
Our testing figures were high during a lockdown. Now lockdown has been lifted, and judging by the crowds in the parks and streets there will sadly be more waves and continued demand for tests.
It's cheap, we're making lots of cash, short term or long term this is a company fighting hard and producing the goods.
I held in AVCT too as a possible future play but much prefer the surety of NCYT.